Cancer Detection and Diagnosis Research
Active
- Assistance listing
- 93.394
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Grant awards
- 9,169 $12,947,433,105 in federal obligations
Program facts
- Assistance types
-
- Project Grant
- Cooperative Agreement
- Block Grant
- Treasury account
-
- 75-0849-0-1-550
- More information
Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.
About this program
The Department of Health and Human Services National Institutes of Health (specifically the National Cancer Institute) funds cancer screening and early detection research, with the most recent award disbursed on September 3, 2026, under Assistance Listing 93.394.
The program supports development of screening and early detection strategies, diagnostic techniques and methods for predicting disease course in cancer patients, diagnostic imaging, tissue specimen analysis, and establishment of tissue resources to facilitate research. Recent awards reflect substantial investment across liquid biopsy platforms (cell-free DNA and RNA biomarkers for melanoma, ovarian, colorectal, hepatocellular, and pancreatic cancers), imaging innovations (MRI contrast agents, photoacoustic imaging, PET imaging of tumor-associated macrophages), point-of-care diagnostic biosensors, and tissue-based detection methodologies including mutation signature extraction and TCR repertoire profiling. The program also funds Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) projects aimed at commercializing detection innovations.
Grant awards are predominantly Project Grants (81% of 7,404 awards), with smaller shares of Cooperative Agreements (15% of 1,384 awards) and Block Grants (4% of 381 awards). The National Cancer Institute dominates funding, providing 3,067 awards worth $9.39 billion in federal dollars obligated, while the broader NIH system (excluding NCI) accounts for 5,833 awards valued at $3.08 billion. Combined federal dollars obligated total $12.95 billion across 9,169 awards since 1977.
Award activity remains steady: the program disbursed 185 awards in 2026 (through September), following 158 in 2025, 203 in 2024, 242 in 2023, and 270 in 2022. Recent awards span $232 thousand to $1.5 million, with representative projects including fluorescent imaging agents for melanoma diagnosis, blood-based biomarkers for early ovarian cancer detection, advanced MRI techniques for brain tumor characterization, and AI-powered platforms for biopsy adequacy assessment.
Multiple grant opportunities remain open or recently posted. The Investigator-Focused Award (R35; PAR-28-037) supports investigator-driven research programs with scientific freedom and funding stability, posted July 30, 2026. Early-stage technology development (RFA-CA-28-001; posted July 14, 2026) solicits proof-of-concept studies on innovative detection platforms. Advanced technology development and validation (RFA-CA-28-002; posted July 14, 2026) supports further refinement of emerging technologies with demonstrated feasibility. Informatics technology opportunities span early-stage development (RFA-CA-27-019), advanced development (RFA-CA-27-020), and sustainment (RFA-CA-27-021) of tools for cancer data management and analysis.
Objective and description
- Objective
To improve screening and early detection strategies and to develop accurate diagnostic techniques and methods for predicting the course of disease in cancer patients. Screening and Early Detection research includes development of strategies to decrea
- Description
To improve screening and early detection strategies and to develop accurate diagnostic techniques and methods for predicting the course of disease in cancer patients. Screening and Early Detection research includes development of strategies to decrease cancer mortality by finding tumors early when they are more amenable to treatment. Diagnosis research focuses on methods to determine the presence of a specific type of cancer; to predict its course and response to therapy, both a particular therapy or a class of agents; and to monitor the effect of the therapy and the appearance of disease recurrence. These methods include diagnostic imaging and direct analyses of specimens from tumor or other tissues. Support is also provided for establishing and maintaining resources of human tissue to facilitate research. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to increase private sector commercialization of innovations derived from Federal research and development; to increase small business participation in Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation.
Eligibility
- Applicant eligibility
The awardee will be a university, college, hospital, public agency, nonprofit research institution or organization, unit of tribal government, or a for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed, and have no more than 500 employees). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.
- Beneficiary eligibility
Any nonprofit or for-profit organization, company, or institution engaged in biomedical research.
- Uses of assistance
Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects. The grants and cooperative agreements may be used for personnel, consultants costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and indirect costs. SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I, and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application. The SBIR Fast-Track Initiative provides additional assistance to applicants by expediting the decision and award of SBIR Phase II funding for scientifically meritorious applications for projects that have a high potential for commercialization. Fast-Track is a parallel review option whereby Phase I and Phase II projects are reviewed concurrently with the aim of reducing or eliminating the funding gap between Phase I and Phase II.
- Length and time phasing of assistance
Grants and cooperative agreements: Average 3 to 4 years and a maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Funding is provided through Monthly Demand Payment System or an Electronic Transfer System. SBIR: Normally, Phase I awards are for 6 months; normally, Phase II awards are for 2 years. STTR: Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2 years.
How to apply
- Criteria for selecting proposals
The major elements in evaluating proposals include assessments of: (1) The scientific merit and general significance of the proposed study and its objectives; 2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technological innovation, originality, or societal importance of the proposed research; (5) the potential of the proposed research for commercial application; (6) the reasonableness of the budget requested for the work proposed; (7) the adequacy and suitability of the facilities and research environment; and (8) where applicable, the adequacy of assurances detailing the proposed means for a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment.
- Award procedure
Grants and cooperative agreements are funded based on scientific merit, program relevance and program balance, consistent with NCI and NIH priorities and strategic plans, and are made annually. Initial award provides funds for the first budget period (usually 12 months) and Notice of Grant Award (Form PHS 1533) indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories, and special conditions, if any. All accepted SBIR/STTR applications are evaluated for scientific and technical merit by an appropriate scientific peer review panel and by a national advisory council or board. All applications receiving a priority score compete for available SBIR/STTR set-aside funds on the basis of scientific and technical merit and commercial potential of the proposed research, program relevance, and program balance among the areas of research.
- Time to approval or disapproval
(Regular Grants) Approximately 10 months. SBIR/STTR: About 7-1/2 months. See website: http://grants1.nih.gov/grants/funding/submissionschedule.htm
- Renewals
Applications submitted for renewal are reviewed and selected for funding on a competitive basis.
- Appeals
A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page http://grants.nih.gov/grants/guide/notice-files/not97-232.html
Grant opportunities
Show 40 more
Latest 50 listed here. See the rest on GovTribe.
Grant awards
Latest 10 of 9,169 listed here. See the rest on GovTribe.
Top recipients by federal obligations
| Rank | Recipient | Federal obligations | Share |
|---|---|---|---|
| 1 | Fred Hutchinson Cancer Center | $471,795,010 | 4% |
| 2 | The Regents Of The University Of California. San Francisco | $432,959,437 | 3% |
| 3 | The Leland Stanford Junior University | $387,606,334 | 3% |
| 4 | The Johns Hopkins University | $347,870,756 | 3% |
| 5 | Sloan-Kettering Institute For Cancer Research | $343,222,173 | 3% |
| 6 | The General Hospital Corporation | $304,649,971 | 2% |
| 7 | The Univeristy Of Texas M.d. Anderson Cancer Center | $300,570,532 | 2% |
| 8 | Research Institute At Nationwide Children's Hospital | $281,756,433 | 2% |
| 9 | The Washington University | $278,005,588 | 2% |
| 10 | Regents Of The University Of Michigan | $252,366,333 | 2% |
10 of 965 recipients listed here. See the rest on GovTribe.
Federal obligations by fiscal year
| Fiscal year | Federal obligations |
|---|---|
| FY2026 | $565,699,505 |
| FY2025 | $1,072,117,215 |
| FY2024 | $1,231,329,539 |
| FY2023 | $1,380,948,503 |
| FY2022 | $1,148,873,421 |
| FY2021 | $979,668,308 |
| FY2020 | $534,460,718 |
| FY2019 | $445,857,118 |
| FY2018 | $426,477,747 |
| FY2017 | $400,904,895 |
| FY2016 | $390,347,617 |
| FY2015 | $369,626,836 |
| FY2014 | $345,405,710 |
| FY2013 | $350,607,243 |
| FY2012 | $355,012,045 |
| FY2011 | $339,830,008 |
| FY2010 | $318,607,243 |
| FY2009 | $279,095,213 |
| FY2008 | $116,577,038 |
| FY2007 | $189,395,924 |
| FY2006 | $299,141,882 |
| FY2005 | $268,005,655 |
| FY2004 | $264,421,057 |
| FY2003 | $225,395,329 |
| FY2002 | $227,092,653 |
| FY2001 | $110,481,610 |
Show all 26
Quick answers
What is Assistance Listing 93.394?
Assistance Listing 93.394 is Cancer Detection and Diagnosis Research, a federal grant program run by National Institutes of Health (Department of Health and Human Services).
What is the CFDA number for Cancer Detection and Diagnosis Research?
Its CFDA number is 93.394: Assistance Listing numbers were called CFDA numbers before 2018.
How much funding has Assistance Listing 93.394 awarded?
9,169 grant awards under 93.394 have obligated $12,947,433,105 in federal funds to 965 recipients.
Who receives the most funding from 93.394?
The recipients obligated the most under Cancer Detection and Diagnosis Research are Fred Hutchinson Cancer Center ($471,795,010), The Regents Of The University Of California. San Francisco ($432,959,437) and The Leland Stanford Junior University ($387,606,334).
How much did 93.394 obligate in fiscal year 2025?
Grants under 93.394 obligated $1,072,117,215 in federal funds in fiscal year 2025.
Are there open grant opportunities under 93.394?
37 of the latest 50 opportunities under 93.394 are open or forecasted. The latest, Investigator-Focused Award (Parent R35), was posted on July 30, 2026.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program